1. Informedia proudly presents the inaugural
conference on
For more details, visit www.globalpharma-summit.com
Best Practice in Service Outsourcing
Conference: 3rd - 4th December 2008 | Venue: Hotel J W Marriott, Mumbai
Global Pharmaceuticals
Research & Manufacturing India 2008
Global Pharmaceuticals
Research & Manufacturing India 2008
n
nActis Biologics
nAll India Institute of
Medical Sciences
nAmgen India
nAstraZeneca Pharma
nCadila Pharmaceuticals
nDr Reddy's Laboratories
nEisai India
nEli Lilly &Co.
nEvolva Biotech
nFDA Maharashtra State
nGlaxoSmithKline
Pharmaceuticals
nInstitute of Clinical
Research India
nNishith Desai Associates
nNovartis
nNycomed Pharma USA
nPfizer
nSandoz
nSanofi–Aventis
nTakeda Global Research
and Development
nUSV
nWockhardt
nWyeth
nZydus Cadila
Abbott India
Top Level Speakers from
Ü
Ü
Ü
Ü
Ü
Find out how to outsource your clinical trials to India
Harness the benefits of Indian CRAMS/CSOs within the
current global pharma business model
Evaluate the implications of moving global R&D offshore
to India
Examine the influence and input of biotech companies in
the Indian pharma market
Learn about the emerging and innovative business
models for partnerships and collaboration
Key Note Speakers
Mr Ranga Iyer
President OPPI and
Managing Director
Wyeth
Mr Suhas Chaudhari
Joint Commissioner
(Greater Mumbai)
FDA Maharashtra State
Uma Nandan Misra
Vice President -
Operations & Site Manager
AstraZeneca Pharma
Mr Ranjit Shahani
Vice Chairman,
Managing Director
and Country President
Novartis
Mr Harjit Singh,
Senior Development
Manager,
Takeda Global Research
and Development, UK
Principal
Media Partner
Media Partners
Online Media Partners
International
Media Partner
2. 10.00 am Evaluating the implications of moving global R&D
offshore vs outsourcing to India
Globalisation of drug development processes
What impact will Indian CROs have on shaping the
global R&D landscape?
Indian CROs view on the offshoring operations -
how do they view their interaction and experiences
when working with US and European pharmas?
l
m
m
Dr Chandrashekhar Potkar
Managing Director, Clinical Research
Pfizer
8.30 am Registration
9.00 am Chairman's Welcome and Opening Address
9.35 am Harnessing the benefits of Indian CRAMS/CSOs
within the current global pharma business model
Comparing CRO (Contract Research Organisation) and
CM (Contract Manufacturing) activities within India,
externally and looking at prospects for future
development
Retrospective analysis of how the CRAMS/CSOs
business model has evolved - where we are now?
Analysis of the long-term prospects for the
CRAMS/CSOs industry and its ultimate effect on
the Indian pharma business
l
m
m
Dr Ish Khanna
Dr Reddy's Laboratories USA
Mr Ranjit Shahani
Vice Chairman, Managing Director and
Country President
Novartis
9.10 am Overview of the Indian pharma sector in an
economic context
What is the current development status of the
industry?
Is the cost advantage of investing in India now
diminishing because of escalating operating costs?
Dealing with the declining ROI of pharma
businesses - proposed solutions to maintain
sustainable growth of the industry
Indian pharma in comparison to other emerging
markets: China, South East Asia and Latin America
Evaluating offshore process outsourcing from a
regulatory and cost perspective
Predicting future prospects: how the Indian economy
is expected to develop - where will we be in 2020?
l
m
m
m
m
l
Globalisation of the Indian pharma industrySession I:
Wednesday 3rd December, 2008DAY 1:
2.40 pm Three years on from the Indian Patents Act 2005
Myths about patents
Features of the Act
Unfinished agenda
Path forward
l
l
l
l
Mr Ranga Iyer
President, OPPI and Managing Director
Wyeth
3.05 pm Pharmacovigilance, PMS and PSUR in India:
Current status and the road map. Assessing the
development of methodologies for monitoring
drug safety
Addressing the increasing concerns over drug safety
and post-approval surveillance
Ensuring proactive pharmacovigilance throughout
the product lifecycle
Improving patient safety by increasing the
transparency of safety data
Transferring the pharmacovigilance advancements of
the West to emerging markets
Exploring the relationship between
pharmacovigilance and risk management
l
l
l
l
l
Mr YK Gupta
Head, Department of Pharmacology,
Zonal Pharmacovigilance Centre
All India Institute of Medical Sciences
10.25 am Morning Refreshments & Networking Break
11.20 am The evolving regulation landscape in India
Discussing the current Indian regulatory environment
Recognising the requirements of Indian regulations
towards approval of drugs developed
Ensuring effective protection of intellectual property
rights and development processes
Standard operating procedures for conducting clinical
trials in India - Schedule Y of the Drugs and Cosmetics
Act in India and guidelines for biomedical research
l
l
l
l
Dr Surinder Singh
Drugs Controller General of India
*
Mr Suhas Chaudhari
Joint Commissioner (Greater Mumbai)
FDA, Maharashtra State
10.55 am Harmonisation of the global pharma regulatory
environment
Evaluating the impact of globalisation on the pharma
regulatory landscape and how this will affect research
and manufacturing processes
Finding a common set of regulations which are
acceptable to all countries
l
l
Indian and worldwide regulatory policies
and legislative framework
Session II:
2.00 pm The viewpoint from two industry specialists on
managing legal and regulatory considerations in
clinical outsourcing
The patent regime and present status of R&D in
India
Government initiatives to shorten the clinical
trials application time
Clinical research landscape in India
Discussing the market prospects for further
development
Analysing the reason for the gap in the amount of
research between India and the rest of the world
Investigating pharmacovigilance practices in India
for the clinical trials market and for future REITs
l
m
l
m
m
l
Dr SK Gupta, Director General
Institute of Clinical Research India
Ms Gowree Gokhale, Partner
Nishith Desai Associates
www.globalpharma-summit.com
For an Updated Conference Programme,
Please log on to:
* Awaiting final confirmation
12.30 pm Luncheon
11.45 am SPEED NETWORKING
The quicker way to do business
3rd - 4th December, 2008
Global PharmaceuticalsGlobal Pharmaceuticals
Research & Manufacturing India 2008
3. 3.30 pm
Dr Sham Nikam, Chief Scientific Officer
Nycomed Pharma USA
Evaluating the current status of drug R&D in India
Drug discovery in India, along with CROs in Indian
pharma industry
Exploring the contract research market from
preclinical to phase 3
Emerging opportunities for conducting exploratory
proof-of concept studies
Trends on outsourcing drug discovery and
development (DD&D)
Producing cost-effective NCEs (New Chemical
Entities) targeting lifestyle, resistant infectious
diseases with improved efficacy and minimal side
effect
Producing a pipeline of promising drug candidates
- DD&D and NCEs
l
m
m
l
m
m
4.15 pm
Dr PM Murali, Managing Director
Evolva Biotech
Building an indigenous value based ecosystem for
cost effective drug discovery in India. Six key
aspects leading to a sub half billion dollar NDA in
the future Indian discovery landscape
INVESTMENT: Arrival of startup VCs redefining the
discovery landscape in India – those with longer
acceptable incubation periods for their ROI and a
higher risk taking ability
EXPERTISE: Influx of returning Indians from
elsewhere with prior experience in drug discovery and
development
FACILITIES: Availability of world class CRAMS/CSOs in
biology, chemistry and pharmacology
RESEARCH CONSULTANTS: Networking with scientific
clusters of excellence, who are willing to collaborate
with industry
INTERFACE & SCALEUP OPERATIONS: English
speaking population and FDA approved facilities –
both available with largest numbers outside United
States
CLINICAL TRIALS: Huge patient population with
diversity and CSIR's efforts in systematic mapping
of heterogenicity, enables effective clinical trials,
pharmacogenomics and pharmacovigilance
l
l
l
l
l
l
Dr Veena Jaguste, Director, Global Development
Operations, Amgen India
4.40 pm The impact of outsourcing on drug development
performance and implications for more effective
collaboration with CROs
Clinical research and trials outsourcing - overcoming
challenges and impediments
Incorporating emerging regions into clinical
development plans - a unique set of opportunities and
challenges
l
l
Mr Harjit Singh, Senior Development Manager
Takeda Global Research and Development UK
5.05 pm Clinical research and trials outsourcing -
challenges and hurdles in India
Conducting phase 1 and 2 clinical trials in India
Clinical quality assurance and its significance in global
drug registration
Clinical safety and risk evaluation in trials
Conducting ethical clinical trials
Managing clinical trial sites successfully
Feasibility studies for investigational site selection
Non clinical: technical and operational procedures and
how to address them
l
l
l
l
l
l
l
3.55 pm Afternoon Refreshments & Networking Break
Mr Sanjeev Saxena
Chairman and CEO
Actis Biologics
Evaluating the influence and input of biotech firms
on the Indian pharma market
Evaluating global biotechnology development and
India's role in the process
Ensuring global biotech opportunities within India and
overseas
Gaining advantage of innovative bio-technologies
Forming partnerships with Indian biotech firms
l
l
l
l
9.10 am
Thursday 4th December, 2008DAY 2:R&D in India: the landscape of opportunities
and challenges
Session III:
8.30 am Registration
9.00 am Chairman's Opening Remarks
Emerging trends in biotechnologySession IV:
Benefits of contract manufacturing
for Indian producers
Session V:
10.40 am Morning Refreshments & Networking Break
9.35 am
Mr Subash Kapre *
Executive Director
Serum Institute of India
Key issues affecting biopharmaceutical
manufacturing
Manufacturing biologics from the CMO (Contract
Manufacturing Organisation) perspective
Where is biopharma manufacturing going in the next
10 years?
Regulatory initiatives impacting biopharmaceutical
development and manufacturing
Entry of biosimilar and bio-generic products
Ensuring quality and safety in bio-processes
Strategies for ensuring product comparability and
safety after manufacturing process changes
l
l
l
l
l
m
10.00 am Global harmonisation and the perception of Indian
CM to the rest of the pharma industry
Evaluating international trends and global
harmonisation opportunities
CMO management throughout the relationship
between CMO and outsourcer lifecycle
Obtaining and understanding how process changes can
affect the structure and biological activity of the final
product (in technology transfer)
Implementing successful approaches in manufacturing
Evaluating the role of globalisation on the regulatory
landscape and manufacturing process
Contract manufacturing - in house vs outsourcing
Emerging fields in the pharma outsourcing market -
why should you outsource manufacturing and risk
costly technology transfer delays?
A critical assessment of the current manufacturing
outsourcing strategies
l
l
l
l
l
l
l
l
Mr Sanjit Lamba, President and CEO
Eisai India
Mr Lakshminarayana Neti, Director Operations
Abbott India
For enquiries write to
jayesh.kanaskar@informedia-india.com5.40 pm Informedia’s Cocktail Reception
5.30 pm Chairman's Closing Remarks and End of Day One
* Awaiting final confirmation
3rd - 4th December, 2008
Global PharmaceuticalsGlobal Pharmaceuticals
Research & Manufacturing India 2008
4. Mr Uma Nandan Misra
Vice President, Operations and Site Manager
AstraZeneca Pharma
11.50 am Case Study - Achieving operational excellence in
a pharma manufacturing plant
Cultural transformation
Aligning manufacturing priorities with business
Identifying & monitoring critical performance
parameters
Engaging all employees for continuous improvement
Achieving excellence in focussed areas
l
l
l
l
l
12.55 pm Luncheon
2.10 pm Implementing strategies to ensure that the
contractors comply with quality agreements
Compliance with GMP requirements
Demonstrating how cGMP is essential for survival in
the pharma business
Gain a competitive edge with a GMP compliant
designed facility
Learn the importance of well written procedures,
validation, documentation and SOPs for cGMP
compliance
l
m
m
m
Dr PM Naik
Project Director
Zydus Cadila
Evolving partnering and business modelsSession VI:
2.35 pm Implementation of risk management strategies in
outsourced manufacturing
Risk and risk management in pharmaceutical and
biopharmaceutical outsourcing
Measuring risk as a preventative technique -
ensuring operational excellence
Identifying, understanding and rating risk
throughout all processes
Implementing effective methods to avoid risk
Identifying and overcoming cost issues in CM
outsourcing
l
l
m
m
m
Mr TS Anand
Director, Contract Manufacturing and Outsourcing
Dr Reddy's Laboratories
3.00 pm Innovative models of collaborating opportunities
with CRAMS/CSOs
Different models of collaboration that can be
established between Indian firms and MNCs
New business and partnership models evolving in
India
In and out licensing of drug discovery research
Partnering opportunities - strategic involvements
l
l
l
l
Ms Mukta Arora
Head of Global Sourcing
Eli Lilly & Co.
3.45 pm External sourcing in the pharma space
Requirements for external sourcing
Basic aspects of external sourcing
Challenges faced by the Indian pharma business as
compared to international businesses and other
sectors
How do you choose the right partner?
Relationship building for the longer term - an essential
part of the pharma business
Legal and contractual issues
l
l
l
l
l
l
Mr Debabrata Gupta
Director and Chief Operating Officer
USV
4.45 pm
4.35 pm
End of Day Two and Close of the Conference
Chairman's Closing Remarks
4.10 pm What are the strengths that the outsourcing
organisation is looking for while selecting the
CRAMS/CSOs?
What the contract givers and contract acceptors
should be aware of to continue long-term business
relationships
Who is the owner of the intellectual property
developed during the cooperation and why?
How to face audits from the outsourcing organisation
to get approved as a CSO
Why continuous communication is essential in such a
relationship
Why the customer should be kept informed of the
failures and mistakes that take place
At what stage does the product need to be optimised
during CRO or CSO?
How process changes from established practice could
affect the customer and the relationship
l
l
l
l
l
l
l
Dr Sunil Kanvinde
Deputy General Manager, Technical Services
Sandoz
11.10 am Two key opinion leaders demonstrate how to
establish successful technology transfer in CMO
to ensure an effective manufacturing process
Technology transfer for outsourcing and contract
manufacture
Implementing technology transfer to ensure an
effective manufacturing process
Critical factors and timelines for a successful
technology transfer
Success factors during process comparability and
validation
Developing and implementing clear quality
agreements with CMOs
Incorporating knowledge to ensure process
comparability, validation and GMP requirements
l
l
l
l
l
l
Mr KK Ambardar, General Manager,
Contract Manufacturing, Cadila Pharmaceuticals
Dr Ashoke Banerjee, Executive Director
GlaxoSmithKline Pharmaceuticals
12.15 pm Panel Session:
Two industry leaders viewpoint on quality
management - developing and implementing
sustainable quality agreements with CMOs
What are the ‘rules of engagement’ between the
sponsor and client for proper management of mutual
quality and quality-regulatory needs in an outsourcing
arrangement?
One size does not fit all - How to design and put a
workable and sustainable quality management system
into practice?
How does a quality agreement separate or link to other
agreements like commercial and technical?
What are the regulatory and legal requirements that
should be addressed in a quality agreement?
How should critical quality activities of change
management, deviations, investigations, product
release, GMP audits and regulatory inspections be
integrated in to a good quality agreement?
l
l
l
l
l
Mr Satish Rajkondawar, Senior Director,
External Manufacturing Site, Sanofi-Aventis
Mr Viswajit Sahu, DGM Contract Manufacturing
Services, Wockhardt
3.25 pm Afternoon Refreshments & Networking Break
3rd - 4th December, 2008
Global PharmaceuticalsGlobal Pharmaceuticals
Research & Manufacturing India 2008
5. About Informedia
Informedia India Pvt Ltd is a leading conference organiser
which specialises in professional high level business
conferences targeted at senior management in a number of
industry sectors. We are a subsidiary company of the
Expomedia Group Plc., a leading International media group
with offices in 13 countries worldwide.
Dedicated to in-depth research, our conferences provide you
with relevant information about what you want to know, when,
and from whom. Straightforward and industry oriented, our
conferences are a very time efficient way to gain a head start
and secure your competitive advantage. Our focused events
create a platform to network with both new and experienced
peers from various industries and feature the most relevant
case scenarios in order to equip you with valuable knowledge
and current know-how.
www.informedia-india.com
Attracting the industry's most powerful and influential delegates
àBusiness Development
àClinical Research Outsourcing
àManufacturing
àDrug Discovery & Development
àMedical Affairs
àPharmaceutical Development
àPharmacoviligance
àPreclinical Development
àProcurement
àProduction Planning & Manufacturing
àPurchasing
àQuality Control & Assurance
àRegulatory Affairs
àRisk & Safety Assessment
Heads of Divisions
àCXOs
àProject Directors
Who will be there?
The Global Pharmaceuticals conference has been
developed with the following executives in mind:
Which industry sectors should attend?
àPharmaceutical Companies
àBiotech Companies
àCROs and CMOs
àPharmaceutical Manufacturers
àResearch Laboratories and Institutes
àBusiness Consulting Firms
àGovernment Institutions and Regulators
àPrivate Equity Funds
àVenture Capitalists
Sponsorship...
helps you to do business and deliver your message to the Global Pharmaceutical market.
Contact our Sponsorship Director on sponsorship@expomediagroup.com or
call +91 22-28500104 in India and +44 (0) 1923 491 067 in the UK to tailor your package
Q.1 Could you benefit from presenting a case study or hosting a
workshop in front of your target audience and demonstrating
your expertise?
If your answer is yes to any of these questions then the
Global Pharmaceuticals Research and Manufacturing India 2008 is
the most important place for you to be.
6 simple questions to determine value from sponsorship
Q.2 Do you want to do business with senior decision makers from
the leading Pharmaceutical and Biotech companies from
India, Asia and the rest of the World?
Q.3 Can you benefit from the impact of outsourcing on Clinical
Research or Contract Manufacturing?
Q.4 Can you provide a solution to the bad perception of
manufacturing from a CMO's perspective?
Q.6 Do you want to collaborate on drug development
performance with CRO's?
Q.5 Are you able to demonstrate the best way to run effective
proof of concept trials?
Sponsoring the Global Pharmaceuticals Research and
Manufacturing India 2008 forum will enable you to:
Raise your company’s profile
Increase your chances of being chosen as the logical choice of
supplier, when they hear and see you can exceed their needs.
Don't pass business opportunities by, whilst your competitors
walk away with them.
Find your all year round marketing solution
There are a limited number of opportunities for you to get
your message across to the leading International
Pharmaceutical and Biotechnology Companies, so act now to
avoid disappointment.
Put simply, you can't afford to miss out!
The conference helps you to overcome common business
development hurdles, like access and face to face networking
with the right people with hours of scheduled networking
time. Global Pharmaceuticals will put you face to face with
people that matter in this industry.
Join our existing partners at this prestigious event
6. REGISTRATION FORM HOTEL INFORMATION
Hotel J W Marriott
www.globalpharma-summit.com
I / We / would like to attend / nominate the following
Please tick
I enclose my Cheque/Draft payable to
INFORMEDIA INDIA PVT. LTD. by post at
204-205, Town Centre, Andheri-Kurla Road,
Sakinaka, Andheri (E), Mumbai - 400059
I am paying by bank transfer (copy attached)
I cannot attend this event but
I would like to purchase the Conference
Documentation for Euro 150 + 12.36 %
Service Tax
Please do not include me on your mailing list
REGISTER NOW in 3 Easy Steps
Call: Sarfraz Patel
Cell: +91 98 33487628
Tel: +91 22 40820183
Fax: +91 22 28509590
Register Online
www.globalpharma-summit.com
1
2
3
Delegate 1 Delegate 2 Delegate 3
Designation
Tel/Mobile/Fax
Email ID
Organisation
Address
Approving Authority
Name
Pin Code
Name/
Designation
Signature
Feesareinclusiveofallprogrammedocuments,lunchonbothconferencedaysandrefreshments.Thefeesdo
not cover travel and accommodation costs. Following completion and return of the registration form
including the authorized signature, full payment is required within 5 working days from receipt of invoice.
PLEASE NOTE: payment must be received prior to the conference date. Admission to the event cannot be
guaranteedifthepaymenthasnotbeenreceivedbyInformediaIndiaPvt.Ltd.
Provided the total fee has been paid, substitutions can be made at any time free of charge. Cancellations
must be received in writing bymail or fax 5 working days before the conference in order to qualify for a Credit
Note which will be valid for 6 months after the date of issue. Thereafter, a Credit note cannot be issued.
Nonpaymentornon-attendancedoesnotconstitutecancellation.If,foranyreason,InformediaIndiaPvt.Ltd.
decides to cancel or postpone this conference and / or workshop/s, Informedia India Pvt. Ltd. is not
responsibleforcoveringairfare,hotelorothertravelcostsincurredbythedelegate.Incaseofcancellationor
postponement, the fee qualifies for a credit note equal in value for any future event organized by Informedia
IndiaPvt.Ltd.
All Intellectual Property Rights in all materials produced or distributed by Informedia India Pvt. Ltd. in
connectionwiththiseventisexpresslyreservedandanyunauthorizedduplication,publicationordistribution
isprohibited.
Event programme content and the event venue can be subject to change without notice and does not impact
theTermsandConditionsspecifiedin1.and2.
With his or her signature, the delegate acknowledges that they have read and understood all terms of this
contractincluding,withoutlimitation,theprovisionsrelatingtocancellationandtopaymentterms.
Terms & Conditions
1.
2.
3.
4.
Please note that 12.36% service tax will be applicable on the above mentioned fees
Fees Package
Euro 1,399Euro 899
For International DelegatesFor Indian Delegates
Conference: 3rd - 4th December 2008 | Venue: Hotel J W Marriott, Mumbai
Juhu Tara Road,
Mumbai - 400 049, India
Tel: +91 22 66933000
Fax: +91 22 66933100
www.marriott.com
Best Practice in Service Outsourcing
Global Pharmaceuticals
Research & Manufacturing India 2008
Global Pharmaceuticals
Research & Manufacturing India 2008